Moderna Sinks 18% on Apparent Leak of Embargoed Phase 3 Melanoma Vaccine Data
Moderna's shares dropped 18% after early-leaked Phase 3 data for its melanoma vaccine showed a 42% reduction in recurrence or death risk, below prior trial results. The stock had surged eightfold this year, trading at 52x forward sales. Full data is expected at ESMO Congress on Saturday. Moderna and Merck developed the vaccine.
How this was made
The 30-second read
Why it matters
The leak undermined investor confidence, leading to an 18% drop despite still positive efficacy numbers.
Market read
High relevance for biotech traders; immediate sell signal for MRNA.
What to watch
Potential partnership benefits with Merck and long‑term pipeline value may cushion the short‑term dip.
Background
Moderna's personalized melanoma vaccine trial data leaked ahead of the ESMO Congress, causing a volatile trading session.
Ticker impact
Moderna shares fell 18% after a leaked Phase 3 melanoma vaccine data showing a 42% risk reduction was posted online before the official ESMO presentation.
likely continued downside as investors reassess valuation and await official data.
The unexpected leak and the lower-than-expected efficacy directly triggered an 18% intraday decline, indicating strong market reaction.
Market effects
Biotech sector may see broader risk aversion toward cancer vaccine pipelines.
US biotech stocks could face short-term pressure.
Limited to biotech investors; no broad market impact.
Counterpoint
If the official data later confirms stronger efficacy, the sell-off could be a buying opportunity.
Key entities
- CompanyModerna
Biotech firm developing the melanoma vaccine.
